Therapeutic Value of SGLT2 Inhibitors in the Management of Congestive Heart Failure

Initially developed as antihyperglycemic agents, sodium-glucose cotransporter 2 (SGLT2) inhibitors have demonstrated therapeutic efficacy at every level of the cardiovascular disease spectrum. Multiple cardiovascular outcome trials have shown that SGLT2 inhibitors significantly reduce hospitalizations for heart failure as well as major adverse events. SGLT2 inhibitors have demonstrated remarkable advantages in lowering the risk of heart failure, even in individuals without diabetes, including those with heart failure. The exact mechanisms by which SGLT2 inhibitors provide cardiovascular protection are still unknown despite their widespread usage, indicating the need for more research. SGLT2 inhibitors have transformed the treatment of cardiovascular disease, providing substantial therapeutic promise for a wide range of patients. They are anticipated to become more and more important in the prevention and management of cardiovascular disease.